Information on Restricted Visitor Policy and Response to COVID-19

Doylestown Health's COVID-19 vaccine offering is restricted by PA Department of Health guidelines.  Find the latest information regarding Doylestown Health's response to COVID, including testing, visitor policies and more. Learn more

Heart and Vascular

Clinical Trials

Clinical Trials

Doylestown Health's robust research program offers patients access to a broad range of clinical trials including heart and vascular studies. Clinical trials test new and innovative treatments and therapies, which are a critical part of advancing medicine. All clinical trials offered by Doylestown Health are approved and closely monitored by the IRB (Institutional Review Board).

Learn more about the importance of clinical trials

Doylestown Health Medical Research

The following trials are coordinated by the Doylestown Health Medical Research Department. For more information, please call 215.345.2119.

Active Trials - Open to Enrollment:

  • Narrowing of Carotid Artery (asymptomatic) - CREST-2

    • Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial
    • An NIH study for patients who have significant narrowing of the carotid artery who have not experienced stroke symptoms (asymptomatic)
    • This four-year study includes close monitoring and intense medical management to reduce stroke risk factors including control of high blood pressure, cholesterol, diabetes, smoking cessation, diet and exercise. The study compares carotid endarterectomy (CEA) with medical management vs carotid stenting (CAS) with medical management vs just medical management
    • Open to enrollment
  • CREST-2 Registry

    • A companion study to the CREST-2 trail offering CREST-2 approved and conditional approved interventionists an opportunity to expand their expertise in performing CAS so they can fully participate in C2
    • All eligible CAS cases performed by study interventionists are registered so they can be reviewed
    • Open to enrollment
  • TAVR and Atrial Fibrillation – ENVISAGETAVI - AF

    • Edoxaban (a new, oral anticoagulant) Compared to Standard Care ( Coumadin)After Heart Valve Replacement Using a Catheter in Patients with Atrial Fibrillation
    • Patients will be followed for 3 year
    • Open to enrollment
  • Coronary Artery Disease - PIONEER III

    • Trial to Assess Safety and Efficacy of a new stent platform for drug eluting stents for the coronary arteries
    • Patients will be followed for 5 years
    • Open to enrollment
  • High Risk Bleeders needing Coronary Stenting – XIENCE- 90

    • The objective of this trial is to evaluate safety of a 3-month dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing Percutaneous Coronary Intervention (PCI) with a Xience stent.
    • Patients are followed for 1 year
    • Open to enrollment

Active Trials - Not Accepting New Patients:

  • Coronary Artery Disease - ABSORB III & IV

    • Enrolled patients in follow up through September 2021
  • Coronary Artery Disease – BIONICS

    • Enrolled patients in follow up through August 2020
  • Coronary Artery Disease – PROMUS CLOSED

    • Enrolled patients in follow up through April 2018
  • Heart Attack – ARTEMIS CLOSED

    • Enrolled patients in follow up through December 2017
  • Peripheral Artery Disease - MIMICS-2

    • Enrolled patients in follow up through June 2019
  • Paroxysmal or persistent atrial fibrillation with high blood pressure - SYMPLICITY AF

    • To evaluate the feasibility of performing both renal artery denervation and pulmonary vein isolation on the same patient to characterize both safety and effectiveness in patients with high blood pressure who have paroxysmal (occasional episodes) or persistent (lasting more than seven days) atrial fibrillation.

Doylestown Health Cardiology - West State Street Office

The following trials are coordinated by Doylestown Health Cardiology, located at 315 W. State Street, Doylestown, PA. For more information, contact Mary O. Bongarzone, MSN, RN, clinical research coordinator, at 215.345.1900.

Active Trials - Open to Enrollment:

  • Dal-Gene: (Dal Cor Pharmaceuticals)

    • Evaluate the effects of dalcetrapib (CETP inhibitor) that raises good cholesterol (HDL)
    • Inclusion: MI/ACS in the last 4-12 weeks
    • Must have specific (AA) genotype to be enrolled – Tested at enrollment
    • Open to enrollment

    • Evaluate the effectiveness of low dose methotrexate in the prevention of recurrent cardiovascular events among stable post MI or multivessel CAD patients with T2DM or Metabolic Syndrome
    • Open to enrollment
  • GOULD: (Amgen)

    • Evaluation of the treatment of hypercholesterolemia by observation (REGISTRY ONLY) of subjects with ASCVD receiving lipid lowering therapy.
    • Are patients with CHD achieving recommended LDL levels? If not, why?
    • Retrospective medical record review and telephone surveys EVERY 6 MONTHS.
    • Open to enrollment
  • VICTORIA: (Merck)

    • A clinical outcomes trial of efficacy and safety of the oral sGC stimulator Vericiguat in patients with heart failure and reduced ejection fraction (HFrEF).
    • Inclusion: NYHA Class II-IV HF; Symptomatic/treated for acute heart failure within the last 3 months. Ejection fraction <45%
    • Open to enrollment

For more information about Doylestown Health's open trials visit the U.S. National Institutes of Health's Clinical Trials database.

Blog Posts

View All Articles

Upcoming Classes and Events

Find a doctor or request an appointment.